Klotho Neurosciences Announces Expiration of Letter of Intent

Rhea-AI Summary

Klotho Neurosciences (Nasdaq: KLTO) announced on October 7, 2025 that its Letter of Intent with Turn Biotechnologies was allowed to expire after evaluation by Klotho's board. The board concluded the proposed transaction did not match the company's long-term strategic plan. Klotho will instead concentrate resources on advancing its Klotho anti-aging protein research pipeline and developing treatments targeting longevity.

The company cited the growing longevity medicine market and aging demographics as rationale for prioritizing its human Klotho protein programs.

NEW YORK, Oct. 7, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO, "Klotho", or "the Company") today announced that its Letter of Intent with Turn Biotechnologies was allowed to expire by the parties.

Following careful evaluation, Klotho's Board of Directors determined that the proposed transaction did not fit its long-term strategic plan. Instead, the Company will focus its resources on advancing its Klotho anti-aging protein research pipeline and development of treatments, where it sees the greatest opportunity to deliver value for patients and shareholders.

The longevity medicine market continues to be one of the fastest-growing global sectors, and Klotho's current pipeline is centered around the human Klotho protein, which is considered a key component in longevity. The world's aging population is expected to hit 2.1 billion by 2050, driving healthcare costs already at 10% of global GDP and projected to exceed $47 trillion by 2030.

About Klotho Neurosciences, Inc.

Klotho Neurosciences, Inc. (NASDAQ: KLTO) is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's disease, and Parkinson's disease. The Company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. Klotho is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.

Forward-Looking Statements

This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

Investor Contact and Corporate Communications:

Jeffrey LeBlanc, CFO
ir@klothoneuro.com

Website: www.klothoneuro.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/klotho-neurosciences-announces-expiration-of-letter-of-intent-302577628.html

SOURCE Klotho Neurosciences, Inc.

FAQ

Why did Klotho Neurosciences (KLTO) let the Letter of Intent with Turn Biotechnologies expire on October 7, 2025?

Klotho's board decided the proposed transaction did not fit the company's long-term strategic plan, so the parties allowed the LOI to expire.

What will Klotho Neurosciences (KLTO) focus on after the LOI with Turn Biotechnologies expired?

The company will focus resources on advancing its human Klotho anti-aging protein research pipeline and treatment development.

Does the LOI expiration with Turn Biotechnologies change Klotho's strategic priorities for 2025?

Yes. Klotho stated it will prioritize its Klotho protein programs over the proposed transaction to pursue its long-term strategy.

Will the expiration of the LOI cause immediate operational changes at Klotho Neurosciences (KLTO)?

Klotho said it will refocus resources toward its pipeline, indicating a strategic reallocation rather than a disclosed operational disruption.

How does Klotho Neurosciences (KLTO) justify focusing on Klotho protein research?

The company cited the fast-growing longevity medicine market and demographic trends as reasons to prioritize its human Klotho protein programs.

Does the announcement state any new deals, financing, or timeline for Klotho Neurosciences (KLTO) programs?

No. The announcement only notes the LOI expired and that the company will concentrate on advancing its existing Klotho pipeline.